Clinical Trials Logo

Clinical Trial Summary

Hereditary Haemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people. The purpose of this study is to provide data regarding the diet and nosebleed frequency using a questionnaire. This will be filled in by people with HHT. The questionnaire has been designed in paper format.


Clinical Trial Description

Hereditary Haemorrhagic Telangiectasia (HHT) affects 1 in 5,000 people, usually causing nosebleeds, skin blood spots, and/or anaemia as a result of bleeding from the nose or gut. The majority of people with HHT also have abnormal blood vessels (arteriovenous malformations) in internal organs such as the lungs, liver and brain. Management of this multisystem disorder is highly challenging. The Lead Applicant has spent 20 years working on this rare disease, and identified multiple areas where more evidence is required to assist clinicians and patients with this lifelong condition. A particular issue is whether the diet influences HHT or its complications in any way. In this study, people will fill in two questionnaires, one giving details of their diet, and another details of their nosebleeds. They will also be asked to consider participating in an accessory study arm which includes weighing food for one week and providing a food diary, in addition to having a single set of blood test. ;


Study Design


Related Conditions & MeSH terms

  • Hereditary Haemorrhagic Telangiectasia (HHT)
  • Telangiectasia, Hereditary Hemorrhagic
  • Telangiectasis

NCT number NCT01692015
Study type Interventional
Source Imperial College London
Contact
Status Completed
Phase N/A
Start date April 2011
Completion date September 2016

See also
  Status Clinical Trial Phase
Completed NCT02983253 - Immunmodulation in Patients With HHT
Completed NCT02690246 - Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia